Katrina W. Copeland
Amgen (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Liver physiology and pathology, Protein Kinase Regulation and GTPase Signaling, Neurobiology and Insect Physiology Research, Postharvest Quality and Shelf Life Management
Most-Cited Works
- → Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain(2010)65 cited
- → Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors(2012)36 cited
- → Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity(2016)34 cited
- → Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors(2015)33 cited
- → Identification of Quinone Imine Containing Glutathione Conjugates of Diclofenac in Rat Bile(2010)30 cited
- → Discovery of triazine-benzimidazoles as selective inhibitors of mTOR(2011)29 cited
- → Development of novel azabenzofuran TRPA1 antagonists as in vivo tools(2014)27 cited
- → 1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition(2018)11 cited
- → Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors(2015)